

Innovative Medicines Initiative 2 funding opportunities January 2019

The **Innovative Medicines Initiative (IMI)** has now launched its **17th Calls for proposals under IMI2**. The Call gives researchers from diverse sectors the opportunity to participate in **ambitious public-private partnerships** that will pave the way for the development of the **medicines of the future**.

Why apply?

- Obtain **research funding**
- Take part in **scientifically excellent, patient-centric** research
- Join unique consortia involving **top teams** from industry, academia, SMEs, regulators, and others
- Benefit from the **expertise, databases, and infrastructures** of consortium partners
- Boost the **visibility and status** of your organisation in Europe and globally and gain **access to new markets**

IMI2 – Call 17

IMI2 – Call 17 was launched on 22 January 2019 and is a standard, two-stage Call for proposals. It includes the following topics:

- Optimising future obesity treatment
- Open access chemogenomics library and chemical probes for the druggable genome
- Intelligent prediction and identification of environmental risks posed by human medicinal products

Read the topic texts:

bit.ly/IMI2call17

Sign up for / catch up on the webinars:

bit.ly/IMI2Call17webinars

Deadline for short proposals:

25 April 2019

How to apply

- The rules and details of how to apply can be found via the Call pages of the IMI website.
- Follow IMI's tips for applicants – see bit.ly/IMItips
- Get advice on finding project partners on our partner search page – bit.ly/IMIfindpartners

Future Calls – topics in the pipeline

The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. Discussions on these topics are still in their early stages. For this reason, the topics may change considerably and they will probably not be ready for inclusion in an IMI Call for proposals for several months. Furthermore, as the discussions advance, it is likely that some topics will be added to this list while others will be dropped. In any case, we hope that this list will give potential applicants a useful glimpse into what is under development in the longer term, and provide additional time to enhance their network.

A pdf with summaries of the topic ideas can be found on the Future Topics page of the IMI website (bit.ly/FutureTopics). We will update this list whenever we have updates on the status of the topics.

Subject area	Topic ideas
Neurodegeneration and other neuroscience priorities	Digital transformation of clinical trial endpoints in pain Placebo effect in pain Psychiatric ratings using intermediate stratified markers - 2
Immunology	Psoriatic arthritis
Infection control including vaccines	New topic(s) under the AMR accelerator platform
Translational safety	Dosing in specific populations Digital pathology
Big data, digital health, clinical trials and regulatory research	ROADMAP 2: need and opportunity for public-private collaborative research to continue the RoadMap efforts Independent observatories of health outcomes for patients being the guardians of health data E-product information. Leveraging digital technology to drive the correct use and understanding of medicines: a user-centric approach to adherence and risk minimisation
Oncology	Patient-reported outcomes and quality of life endpoints
Facilitating the translation of advanced therapies to patients in Europe	Accelerating research and development of Advanced Therapies ATMP Patient Registries Outcomes Data and Evidence CAR-Ts Innovative Manufacturing of Advanced Therapeutic Medicinal Products, ATMPs
Other enablers of research topics	Handling of biologic drug products

About the Innovative Medicines Initiative

At IMI, we are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.

We do this by facilitating collaboration between the key players involved in healthcare research.

We are a partnership between the European Union and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), and have a €3.3 billion budget for the period 2014-2020.

Since our launch in 2008, we have launched over 100 projects in areas as diverse as dementia, pain, diabetes, autoimmune disease and antimicrobial resistance as well as tools for drug discovery and development, clinical trial design, and drug and vaccine safety.

Stay in touch

Visit the IMI website:

www.imi.europa.eu

Sign up to the IMI Newsletter:

bit.ly/IMINewsletter

Follow us on Twitter:

[@IMI_JU](https://twitter.com/IMI_JU)

Join the IMI group on LinkedIn:

bit.ly/LinkedInIMI

E-mail us:

infodesk@imi.europa.eu

Get support:

bit.ly/IMIsupport